PPARG and Other metabolic disease: However, the chronic administration of PPAR agonists in human for the treatment of metabolic diseases may importantly increase the risk of developing cardiovascular diseases (e.g., for PPARγ agonists) and specific cancers (e.g., for PPARα agonists).